Pharmaceuticals, Biotechnology and Life Sciences
U.S. Food and Drug Administration(FDA) has accepted for review the Alexion Pharmaceuticals’s supplemental Biologics License Application (sBLA) to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
InDex Pharmaceuticals Holding AB has appointed Johan Giléus as new Chief Financial Officer (CFO) who will take over his new duties from May 1, 2017.
Celyad is about to kick the THINK trial in the USA, after the U.S. FDA authorized its initiation. THINK evaluates NKR-2 CAR-T cells in seven indications, five solid cancers and two hematological malignancies.
OptiBiotix health has signed a manufacturing, supply, and profit sharing deal with Sacco, one of Europe’s leading suppliers of probiotics ingredients.
Valisek, a joint venture between ValiRx, a clinical stage biotechnology company and Tangent Reprofiling Limited, plans to add a third clinical site, in Tbilisi, Georgia.
Notable news in the pharmaceutical and biotech markets includes a slew of mergers and acquisitions, new drug trails and product launches as industry leaders search for competitive advantage and increased revenue streams.
Innate Pharma has reported its consolidated financial results for the year ended December 31, 2016.
Swedish Orphan Biovitrum AB known as Sobi said Tuesday that the FDA has approved increased shelf life and extended out-of-refrigeration for Orfadin capsules.
CPhI & P-MEC China 2017, hosted by UBM EMEA and China Chamber of Commerce of Medicines & Health Products Importers & Exporters (CCCMHPIE), and co-organized by Shanghai UBM Sinoexpo, will open its doors on June 20-22, 2017 in Shanghai.
IDMC has recommended that all three doses continue to be tested in the ongoing Phase 2b trial for BGS-649, an inhibitor for obese men with hypogonadotropic hypoganadism.